Quadrant Capital Group’s Sana Biotechnology SANA Stock Holding History

Quadrant Capital Group’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,480	Closed	-$4.26K	–	2318
2026 Q1	$4.26K	Hold	1,480	–	–	﹤0.01%	2388
2025 Q4	$6.02K	Hold	1,480	–	–	﹤0.01%	2326
2025 Q3	$5.25K	Buy	+1,480	New	+$5.35K	﹤0.01%	2317
2025 Q2	–	Sell	-2,068	Closed	-$3.48K	–	2367
2025 Q1	$3.48K	Buy	2,068 +1,220	+144%	+$3.41K	﹤0.01%	2429
2024 Q4	$1.38K	Buy	848 +56	+7%	+$167	﹤0.01%	2546
2024 Q3	$3.29K	Hold	792	–	–	﹤0.01%	2407
2024 Q2	$4.33K	Hold	792	–	–	﹤0.01%	2333
2024 Q1	$7.92K	Hold	792	–	–	﹤0.01%	2182
2023 Q4	$3.23K	Buy	792 +321	+68%	+$1.18K	﹤0.01%	2373
2023 Q3	$1.82K	Hold	471	–	–	﹤0.01%	2412
2023 Q2	$2.81K	Hold	471	–	–	﹤0.01%	2341
2023 Q1	$1.54K	Sell	471 -30	-6%	-$120	﹤0.01%	2473
2022 Q4	$1.98K	Buy	501 +471	+1,570%	+$2.3K	﹤0.01%	2419
2022 Q3	$0	Hold	30	–	–	﹤0.01%	2786
2022 Q2	$0	Sell	30 -1	-3%	-$6	﹤0.01%	2705
2022 Q1	$0	Buy	+31	New	+$251	﹤0.01%	2671

Other funds holding SANA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

Quadrant Capital Group's SANA Position: Q2 2026 in Review

Quadrant Capital Group sold out of Sana Biotechnology (SANA) in Q2 2026, closing a stake of 1,480 shares — an estimated $4.26K sold.

Quadrant Capital Group first reported a position in SANA in Q1 2022 and held it in 16 quarters. The position peaked at $7.92K in Q1 2024. 211 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

Quadrant Capital Group reported no remaining Sana Biotechnology position as of Q2 2026 after selling out during the quarter.
Quadrant Capital Group sold 1,480 Sana Biotechnology shares in Q2 2026, an estimated $4.26K.
Quadrant Capital Group first reported a position in Sana Biotechnology in Q1 2022 and held it in 16 quarters.
Quadrant Capital Group's Sana Biotechnology position peaked at $7.92K in Q1 2024.
211 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.